Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

NCT05746208 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT05746208
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05746208 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
Lead sponsor
University of California, San Francisco
Phase
Phase 2
Overall status
Recruiting
Start date
July 17, 2023
Completion date
March 31, 2028
Enrollment
29 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

high grade neuroendocrine carcinoma, any site, neuroendocrine tumors, well-differentiated neuroendocrine carcinoma